What are Immune checkpoint inhibitor drugs?

Immune checkpoint inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting PD-1). 1 are currently marketed, with 21 more in clinical development.

What are the marketed Immune checkpoint inhibitor drugs?

Marketed Immune checkpoint inhibitor drugs include Immune Checkpoint Inhibitors.

Immune checkpoint inhibitor

1 marketed 11 in Phase 3 9 in Phase 2 1 in Phase 1

This page covers all Immune checkpoint inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PD-1, IL-2R, PD-1/PD-L1.

Targets

PD-1 · IL-2R · PD-1/PD-L1 · CD137 · LAG-3

Marketed (1)

Immune Checkpoint Inhibitors · The Central Hospital of Lishui City · Oncology
Immune checkpoint inhibitors block inhibitory signals on T cells, allowing the immune system to recognize and attack cancer cells.

Phase 3 pipeline (11)

Immune checkpoint inhibitor · John L. Villano, MD, PhD · Oncology
Immune checkpoint inhibitors block inhibitory signals on T cells, allowing the immune system to recognize and attack cancer cells.
GTX-104 · Grace Therapeutics Inc. · Oncology
GTX-104 is a small molecule that targets the PD-1/PD-L1 pathway.
Rescue medications for chemotherapy · Merck Sharp & Dohme LLC · Oncology
This drug works by inhibiting the activity of the PD-1 receptor, allowing the immune system to attack cancer cells.
anti-IL-2R · Hoffmann-La Roche · Immunology
anti-IL-2R drugs target the interleukin-2 receptor to prevent T-cell activation.
AGS (Experimental) · Ahn-Gook Pharmaceuticals Co.,Ltd · Oncology
AGS is an experimental drug that targets the PD-1/PD-L1 pathway.
Reference0912 · Sun Pharma Advanced Research Company Limited · Oncology
Reference0912 is a drug that targets the PD-1 receptor.
Investigational products administration · Assistance Publique - Hôpitaux de Paris · Oncology
This drug is an investigational product that targets the PD-1/PD-L1 pathway.
SPARC1104 modified dose regimen I · Sun Pharma Advanced Research Company Limited · Oncology
SPARC1104 modified dose regimen I is a drug that targets the PD-1/PD-L1 pathway.
IN-C006 Peri inj. · HK inno.N Corporation · Oncology
IN-C006 Peri inj. is a drug that targets the PD-1/PD-L1 pathway.
HL301(Experimental) · Hanlim Pharm. Co., Ltd. · Oncology
HL301 is an experimental drug that targets the PD-1/PD-L1 pathway to enhance anti-tumor immune response.
Praga formulation · EMS · Oncology
Praga formulation is a drug that works by targeting the PD-1/PD-L1 pathway to modulate the immune system.

Phase 2 pipeline (9)

Biological analysis · Hospices Civils de Lyon · Oncology
This drug targets the PD-1 receptor to modulate the immune response.
Durvalumab plus Olaparib · QuantumLeap Healthcare Collaborative · Oncology
PD-1 inhibitor
Adebrelimab combined with chemotherapy · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Oncology
Immune checkpoint inhibitor
Anti-PD-1 Therapy · Novita Pharmaceuticals, Inc. · Oncology
Inhibits PD-1 receptor
Keytruda Injectable Product · PDC*line Pharma SAS · Oncology
PD-1 inhibitor
Immunotherapy monotherapy · Bristol-Myers Squibb · Oncology
Immune checkpoint inhibitor
Cohort 1 neo-adjuvant · William Sikov MD · Oncology
This drug targets the PD-1 receptor to inhibit cancer cell growth.
CetuGEX™ · Glycotope GmbH · Oncology
CetuGEX targets the CD137 receptor to stimulate an immune response against cancer cells.
Adjuvant treatment · GERCOR - Multidisciplinary Oncology Cooperative Group · Oncology
This drug works by enhancing the body's immune response to cancer.

Phase 1 pipeline (1)

ALT803 · Brenda Cooper, MD · Oncology
Nucleic acid-based immunotherapy